Outcomes of patients with cerebral microbleeds undergoing percutaneous coronary intervention and dual antiplatelet therapy
Heart and Vessels · 2024
DOI: 10.1007/s00380-024-02404-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart and Vessels, 2024. Verfasst von Masashi Fujino und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Suita, Osaka, Japan. fujinom@ncvc.go.jp. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Coronary Artery Disease, Cerebral Hemorrhage, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: The Intramural Research Fund for Cardiovascular disease of the National Cerebral and Cardiovascular Center.
Abstract (Originalsprache)
INTRODUCTION: Cerebral microbleeds (CMBs) on brain magnetic resonance imaging (MRI) are predictive of intracerebral hemorrhage (ICH). However, the risk of ICH in patients with CMBs who undergo percutaneous coronary intervention (PCI) while receiving dual antiplatelet therapy (DAPT) is unclear. MATERIALS AND METHODS: We conducted a study on 329 consecutive patients with coronary artery disease who underwent PCI and were evaluated using a 3T MRI scanner. Based on T2*-weighted imaging, patients were classified into three groups: no CMBs, < 5 CMBs, or ≥ 5 CMBs. We determined the occurrence of ICH during follow-up. RESULTS: At least 1 CMB was found in 109 (33%) patients. The mean number of CMBs per patient was 2.9 ± 3.6. Among the 109 patients with CMBs, 16 (15%) had ≥ 5 CMBs. Coronary stent implantation was performed in 321 patients (98%). DAPT was prescribed for 325 patients (99%). During a mean follow-up period of 2.3 years (interquartile range, 1.9-2.5 years), ICH occurred in one patient (1.1%) with four CMBs. There were no significant differences in the incidence of ICH (0% vs. 1.1% vs. 0%; p = 0.28). However, the rate of DAPT at 6 months of follow-up was significantly lower in patients with ≥ 5 CMBs than in patients with no CMBs or < 5 CMBs (89% vs. 91% vs. 66%, p = 0.026). Furthermore, there were no significant differences in systemic blood pressure during follow-up (123 ± 16 vs. 125 ± 16 vs. 118 ± 11 mmHg; p = 0.40). CONCLUSION: Although a substantial number of patients who underwent PCI had cerebral microbleeds, at approximately two years of follow-up, intracerebral hemorrhage was very rare in our study population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Suita, Osaka, Japan. fujinom@ncvc.go.jp.
- Department of Cardiovascular Medicine, Suita, Osaka, Japan.
- Stroke and Cerebrovascular Disease, Suita, Osaka, Japan.
- Department of Primary Care and Emergency Medicine/Healthcare Epidemiology, Kyoto university, Kyoto, Japan.
- Radiology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
- Preventive Cardiology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
Förderung
- The Intramural Research Fund for Cardiovascular disease of the National Cerebral and Cardiovascular Center
Zitieren
APA
Fujino, M., Noguchi, T., Torii-Yoshimura, T., Okuno, Y., Morita, Y., Nishimura, K., Otsuka, F., Kataoka, Y., Asaumi, Y., Yamagami, H., & Yasuda, S. (2024). Outcomes of patients with cerebral microbleeds undergoing percutaneous coronary intervention and dual antiplatelet therapy. Heart and Vessels. https://doi.org/10.1007/s00380-024-02404-7
Vancouver
Fujino M, Noguchi T, Torii-Yoshimura T, Okuno Y, Morita Y, Nishimura K, et al. Outcomes of patients with cerebral microbleeds undergoing percutaneous coronary intervention and dual antiplatelet therapy. Heart and Vessels. 2024. doi:10.1007/s00380-024-02404-7
BibTeX
@article{Fujino2024,
author = {Fujino, Masashi and Noguchi, Teruo and Torii-Yoshimura, Takako and Okuno, Yoshinori and Morita, Yoshiaki and Nishimura, Kunihiro and Otsuka, Fumiyuki and Kataoka, Yu and Asaumi, Yasuhide and Yamagami, Hiroshi and Yasuda, Satoshi},
title = {Outcomes of patients with cerebral microbleeds undergoing percutaneous coronary intervention and dual antiplatelet therapy},
journal = {Heart and Vessels},
year = {2024},
doi = {10.1007/s00380-024-02404-7}
}
EUVIMED